HolderBook

Partner Investment Management, L.P.

Reported holdings as of Q4 2019, from 5 quarterly filings.

This filer last reported in Q4 2019; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1442276
Reported value
$13.9M
Positions
41
Top 10 weight
48.1%
Filed
2020-02-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
AUDENTES THERAPEUTICS INCBOLD$1.1M17,7957.65%+6.43pp5q-29.9%-$453.4K
ALEXION PHARMACEUTICALS INCALXN$911.0K8,4216.54%+2.83pp2q-62.0%-$1.5M
ALLENA PHARMACEUTICALS INCALNAQ$776.0K284,2855.57%+3.65pp5qHELD
GILEAD SCIENCES INCGILD$708.0K10,8985.08%+1.99pp3q-61.8%-$1.1M
PENUMBRA INCPEN$608.0K3,6994.37%+1.47pp5q-70.5%-$1.5M
ZIMMER BIOMET HOLDINGS INCZBH$552.0K3,6893.96%-0.19pp5q-79.1%-$2.1M
BIOGEN INCBIIB$546.0K1,8393.92%-newNEW
NEVRO CORPNVRO$531.0K4,5153.81%+2.96pp5q-21.7%-$147.2K
ELEVANCE HEALTH INC FORMERLYELV$504.0K1,6693.62%-newNEW
HUMANA INCHUM$494.0K1,3473.55%-newNEW
THE CIGNA GROUPCI$453.0K2,2163.25%+1.40pp2q-68.9%-$1.0M
IQVIA HLDGS INCIQV$452.0K2,9263.25%+1.05pp4q-65.8%-$871.4K
BIOMARIN PHARMACEUTICAL INCBMRN$451.0K5,3293.24%-0.15pp3q-81.8%-$2.0M
AERIE PHARMACEUTICALS INCAERI$436.0K18,0353.13%+2.58pp2q+7.8%+$31.5K
ALLERGAN PLCAGN$436.0K2,2823.13%+1.01pp4q-69.1%-$972.9K
ARENA PHARMACEUTICALS INCARNA$431.0K9,4843.09%+0.83pp5q-67.2%-$881.3K
CENTENE CORP DELCNC$430.0K6,8383.09%-newNEW
NOVARTIS AGNVS$392.0K4,2702.81%+1.23pp2q-60.1%-$591.3K
HCA HEALTHCARE INCHCA$345.0K2,3352.48%+0.93pp5q-68.9%-$763.1K
PFIZER INCPFE$294.0K7,4922.11%-newNEW
ICU MED INCICUI$258.0K1,3811.85%-newNEW
DERMIRA INCDERM$256.0K16,8921.84%+1.51pp4q-43.7%-$198.6K
ICON PUB LTD COICLR$241.0K1,4021.73%+0.92pp3q-56.4%-$311.1K
UNITEDHEALTH GROUP INCUNH$233.0K7911.67%-newNEW
IRHYTHM HOLDINGS INCIRTC$231.0K3,3891.66%+0.04pp5q-73.4%-$638.8K
IMMUNOMEDICS INCIMMU$230.0K10,8801.65%-newNEW
ABBOTT LABORATORIESABT$223.0K2,5651.60%-newNEW
MOLINA HEALTHCARE INCMOH$188.0K1,3871.35%flat5q-80.7%-$785.6K
EDWARDS LIFESCIENCES CORPEW$184.0K7881.32%-0.08pp5q-78.8%-$684.4K
STANDARD BIOTOOLS INCLAB$132.0K37,8560.95%+0.67pp4q+7.1%+$8.7K
CATALENT INCCTLT$126.0K2,2310.90%-0.20pp3q-83.5%-$639.9K
MorphoSys AG$126.0K9940.90%-newNEW
ABBVIE INCABBV$112.0K1,2690.80%-newNEW
AXONICS INCAXNX$110.0K3,9780.79%+0.70pp2q+105.4%+$56.4K
CARDIOVASCULAR SYS INC DELCSII$96.0K1,9850.69%+0.21pp5q-66.4%-$190.1K
VERTEX PHARMACEUTICALS INCVRTX$95.0K4340.68%-newNEW
HALOZYME THERAPEUTICS INCHALO$82.0K4,6500.59%-newNEW
AMARIN CORP PLCAMRNXXXX$81.0K3,7570.58%-newNEW
COHERUS ONCOLOGY INCCHRS$68.0K3,7710.49%+0.22pp4q-51.7%-$72.8K
ACORDA THERAPEUTICS INCACOR$37.0K18,3420.27%+0.17pp2q-7.7%-$3.1K
ENDOLOGIX INCELGXQ$4.0K2,4400.03%+0.01pp2q-15.3%

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 36.7%Insurance 16.5%Medical Devices 13.2%Healthcare Services 2.5%Not classified 31.1%
 
SectorValueShare
Biotech & Pharma$5.1M36.7%
Insurance$2.3M16.5%
Medical Devices$1.8M13.2%
Healthcare Services$345.0K2.5%
Not classified$4.3M31.1%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q4 2019$13.9M41143234248.1%45
Q3 2019$58.4M692814254041.1%45
Q2 2019$94.2M812028282841.7%45
Q1 2019$86.5M893517363433.2%45
Q4 2018$80.1M88000038.3%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.